Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma

Insider Monkey2024-12-18

We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492297953?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H1YYmML3UCGwi73dzhf35g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/84c945cd5e3d7d75e6891dc74af98b9d","is_english":true,"pubTime":"2024-12-18 16:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492297953","market":"us","top_or_hot":-1,"title":"Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma","media":"Insider Monkey","content":"<div>\n<p>We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tempus-ai-inc-tem-expands-080034636.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tempus-ai-inc-tem-expands-080034636.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other ...</p>\n\n<a href=\"https://finance.yahoo.com/news/tempus-ai-inc-tem-expands-080034636.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930573.SGD","symbol_name":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","start_time":0,"source_url":"https://finance.yahoo.com/news/tempus-ai-inc-tem-expands-080034636.html","article_id":"2492297953","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H1YYmML3UCGwi73dzhf35g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/84c945cd5e3d7d75e6891dc74af98b9d"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492297953","pubTimestamp":1734508834,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street.In this article, we are going to take a look at where Tempus AI, Inc  stands against the other AI stocks.There is a growing concern in Silicon Valley that the progress around artificial intelligence is slowly “losing steam”. CNBC’s Deirdre Bosa explores whether AI progress is slowing, and what it means for the industry. Early signs of struggle are bubbling up in major tech names. As highlighted by Bosa, the first sign of things slowing down has been a lack of progression between models. OpenAI has led the pack in AI advancements, with each of the new models of ChatGPT exponentially better than the last.READ NOW:10 AI Stocks Taking Wall Street by StormandTop 10 AI Stocks on Latest News and Analyst Ratings. “While Orion’s performance ended up exceeding that of prior models, the increase in quality was far smaller compared with the jump between GPT-3 and GPT-4, the last two flagship models the compa","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1852331112.SGD":"Blackrock World Technology Fund A2 SGD-H","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","TEM":"Tempus AI","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","PSQ":"纳指反向ETF","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","NVIW.SI":"NVDA 3xLongSG261006","TSYW.SI":"TESLA 3xLongSG261006","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","QLD":"纳指两倍做多ETF","USAW.SI":"AMZN 3xLongSG261006",".IXIC":"NASDAQ Composite","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","BK4538":"云计算","BK4579":"人工智能","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","TQQQ":"纳指三倍做多ETF","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","GOOGL":"谷歌A","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","USJW.SI":"ALPHAB 3xLongSG261006","IE00BKDWB100.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5H\" (SGDHDG) ACC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","PSNL":"Personalis","LU2092937148.SGD":"Blackrock ESG Multi-Asset A8 SGD-H","SG9999000418.SGD":"Aberdeen Standard Global Technology SGD","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0096362180.USD":"CT (LUX) I GLOBAL FOCUS \"DU\" (USD)","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","SQQQ":"纳指三倍做空ETF","QID":"纳指两倍做空ETF","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC"},"translate_title":"Tempus AI，Inc(TEM)扩大与Personalis的合作伙伴关系，推进生物制药的超灵敏MRD测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1,"PSNL":1,".IXIC":0.77,"GOOGL":0.67,"PSQ":0.6,"NVIW.SI":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"USJW.SI":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other AI stocks.\nThere is a growing concern in Silicon Valley that the progress around artificial intelligence is slowly “losing steam”. CNBC’s Deirdre Bosa explores whether AI progress is slowing, and what it means for the industry. Early signs of struggle are bubbling up in major tech names. As highlighted by Bosa, the first sign of things slowing down has been a lack of progression between models. OpenAI has led the pack in AI advancements, with each of the new models of ChatGPT exponentially better than the last.\nREAD NOW: 10 AI Stocks Taking Wall Street by Storm and Top 10 AI Stocks on Latest News and Analyst Ratings\nUnfortunately, the same can’t be said about today. OpenAI's highly anticipated model Orion was expected to be a ground-breaking system bringing us closer to AGI. However, the initial vision is being scaled back.\n\n“While Orion’s performance ended up exceeding that of prior models, the increase in quality was far smaller compared with the jump between GPT-3 and GPT-4, the last two flagship models the company released, according to some OpenAI employees who have used or tested Orion”.\n-The Information\n\nThe same roadblocks have been happening to other AI models, such as that by Anthropic. Just like OpenAI, Anthropic is also witnessing a timetable slip for the release of its long-awaited Claude model called 3.5 Opus.\n\n\"The AGI bubble is bursting a little bit. It's become clear that 'different training approaches' may be needed to make AI models work really well on a variety of tasks.\"\n-Margaret Mitchell, chief ethics scientist at AI startup Hugging Face, to Bloomberg.\n\nEven some of the big tech giants aren't enthusiastic about the progress AI has been making. Speaking during the New York Times annual DealBook summit at Jazz at Lincoln Center, Sundar Pichai stated how generative AI won’t be changing lives in 2025— at least, not more than it already has.\n\n“I think the progress is going to get harder. When I look at [2025], the low-hanging fruit is gone. The hill is steeper ... You’re definitely going to need deeper breakthroughs as we get to the next stage”.\n- Sundar Pichai\n\nHowever, if progress is plateauing, it has to do with scaling laws. Anthropic CEO Dario Amodei states that the scaling laws are a misnomer. He emphasizes that while these patterns have historically guided AI development—suggesting that increasing data and computational power leads to improved AI capabilities—they are not guaranteed to continue indefinitely.\nAs such, AI companies have been turning to synthetic AI, i.e. data generated artificially. The Information reports that Orion was produced based on synthetic data. However, the problem has been that low-quality data, in turn, leads to low-quality performance. As such, with leading tech companies poised to unveil new models over the next eighteen months, their pace of progress—or lack thereof—has the potential to dramatically redefine the dynamics of the competition.\nFor this article, we selected AI stocks by going through news articles, stock analysis, and press releases. These stocks are also popular among hedge funds.\nWhy are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\n A healthcare professional preparing a vial for a patient in need of biotechnology services. \nTempus AI, Inc (NASDAQ:TEM)\nNumber of Hedge Fund Holders: 7\nTempus AI, Inc (NASDAQ:TEM) is a healthcare technology company that provides AI-enabled precision medicine solutions. On December 16, the company announced that it has expanded its relationship with Personalis, Inc. (NASDAQ:PSNL), a provider of advanced genomic sequencing and analytics solutions. The companies had initially collaborated in November 2023 to bring ultra-sensitive MRD testing to market, a testing procedure used to check if a cancer treatment is working.\nThey launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus serves as the exclusive commercial diagnostic partner for Personalis’ ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx. This product focuses on breast and lung cancers as well as immunotherapy for solid tumors. Strong market interest has led the companies to expand their relationship, where Tempus will offer Personalis’ MRD product to pharmaceutical and biotech companies.\n\nWhile we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus’ integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products. We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity”.\n-Chris Hall, CEO of Personalis.\n\nOverall TEM ranks 10th on our list of the AI stocks that are dominating Wall Street. While we acknowledge the potential of TEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TEM but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.   \nREAD NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.   \nDisclosure: None. This article is originally published at Insider Monkey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492297953"}